# OptiBiotix Health Plc Successful launch of LPLDL and SlimBiome products

- Link: https://www.directorstalkinterviews.com/optibiotix-health-plc-successful-launch-lpldl-slimbiome-products/412729201
- Published: 2017-05-16T07:14:33+01:00
- Author: Giles Arbor

**OptiBiotix Health plc** (LON:OPTI), a life sciences business developing compounds
to tackle obesity, high cholesterol, and diabetes announced today the successful
launch of its SlimBiome® and LPLDL® products at the Vitafoods Europe tradeshow in
Geneva from the 9-11 of May 2017. The event provided the opportunity to connect 
with 16,500 industry decision makers from the supplements, nutraceutical, functional
food and beverage industries. This is viewed as one of the world’s leading trade
fairs for the food and drinks industry.

OptiBiotix launched the first of its range of heart health products containing LPLDL
® called CholBiome and CardioBiome, and its SlimBiome® weight management technology.
Both product types were exhibited in the New Products Zone and at Sacco’s and Nutrilinea’s
stands. Sacco and Nutrilinea are OptiBiotix’s European manufacturing and formulation
partners and have an extensive European network to maximise the commercial opportunity
provided by these products.

Both LPLDL® and SlimBiome® were extremely well received with high interest in the
distribution and sale of these products from partners across Europe, Japan, India,
Asia, Australia and the USA. OptiBiotix’s recent appointments, Commercial Director
Per Rehne, and Sales and Marketing Director Christina Wood, are leading the commercialisation
and internationalisation of these products in global markets. Christina is leading
the commercialisation of SlimBiome whilst Per is leading the commercialisation of
LPLDL®.

> **Stephen O’Hara, CEO of OptiBiotix Health Plc, commented:** “We are extremely
> pleased with the very high level of interest from both national and multinational
> companies interested in selling our products. This has already resulted in some
> companies sending through draft contracts. The Company anticipates that this interest
> will start to generate revenues from both ingredient supply, and as a component
> in high value white label and branded formulations and presentations, across multiples
> territories. We are at the start of the commercialisation process but are really
> excited at the high level of interest in our products. We look forward to building
> commercial partnerships, market presence, and multiple revenue streams in both
> consumer health and pharmaceutical markets around the world.”

Share on: